Thyroglobulin: The Main Marker in the In Vitro Diagnosis and Treatment of Differ

Posted by Jerry Carter on August 23rd, 2019

Thyroid cancer is a common endocrine malignant tumor, which is traditionally divided into differentiated thyroid cancer, undifferentiated thyroid cancer and medullary thyroid cancer. Differentiated thyroid cancer is divided into papillary and follicular adenocarcinoma. Undifferentiated thyroid cancer is rare and has poor prognosis. Medullary thyroid cancer originates from parafollicular cells (C cells), which belongs to one of neuroendocrine tumors. About 25% of patients with multiple type 2 endocrine tumors have medullary thyroid cancer. At present, the main means to diagnose thyroid cancer are thyroid cell puncture, intraoperative pathological freezing and post-operative paraffin pathological section. Although thyroid cell puncture can achieve the diagnostic significance, its clinical application is limited by its low positive rate, so the method of clinical diagnosis of thyroid cancer is mainly based on the following. By intraoperative freezing or paraffin section after operation. In addition, in the serology of thyroid cancer, although the progress of research on thyroid cancer tumor markers is very fast, there is no consensus in clinical recognition so far, indicating that the research on thyroid cancer tumor markers is still in the initial stage, which is worth further development.


Summary of Thyroglobulin

Thyroglobulin is a biological macromolecule with 2750 amino acids and a molecular weight of 3300. Its gene expression is regulated by TTF-1 and Pax-8. Its physiological function is mainly to promote the release of T3 and T4 into the blood under the action of TSH. Mutations in thyroglobulin can induce nonsecretory goiter to develop into thyroid cancer.

1. Study of thyroglobulin in thyroid cancer

Besic et al. detected serum thyroglobulin in 327 patients with thyroid follicular adenoma diagnosed before operation, and then counted them by multivariate logistic regression according to the pathological diagnosis after operation. The results showed that there was a positive correlation between serum thyroglobulin concentration > 300ng/mL and the incidence of thyroid. The elevation of serum thyroglobulin concentration can be used as a marker for predicting the incidence of thyroid cancer. As for lymph node metastasis of thyroid cancer, the serum thyroglobulin concentration of thyroid cancer patients with peripheral lymph node metastasis is higher than that of patients without lymph node metastasis, and there is statistical significance through statistical analysis, which has been confirmed by Low et al., indicating that the serum thyroglobulin concentration is higher than that of patients without lymph node metastasis. The concentration of thyroglobulin can be used not only as a useful cancer marker for prediction, but also to determine whether the tumor has peripheral lymph node metastasis. More importantly, Kebebew et al. measured thyroglobulin in jugular vein and forearm vein blood of 14 patients with thyroid cancer. The results showed that the concentration of thyroglobulin in jugular vein blood was significantly higher than that in forearm vein blood, and the farther away from the jugular vein, the lower the concentration. It is inferred that serum thyroglobulin can not only be used as a tumor marker for predicting thyroid cancer, but also be used to estimate the primary focus of thyroid cancer according to the concentration difference in different directions.

In vitro diagnostics (IVDs) provide more than 80% of the information needed for medical decision-making, such as disease diagnosis, early diagnosis, guidance, prognosis judgment, curative effect monitoring and disease prediction and early warning, through qualitative or quantitative analysis of biomarkers in isolated specimens. It not only supports the normal development of modern medical activities, but also affects trillion yuan of doctors in the course of treatment. Medical consumption is also a necessary means to achieve precise medical treatment, graded diagnosis and treatment, and to support the construction of healthy China.

IVD technology presents development trends

IVD is the gathering place of the frontier progress of science, engineering and medicine. Its technological development is changing with each passing day, which promotes the improvement and expansion of the clinical diagnostic performance and application performance of IVD products.

Creative Biolabs has developed IVD Antibody Development Platform to improve a wide range of customized research and development services, including IVD Antibody Development, Antibody & Protein Conjugation, IVD Kit Development, etc. Specifically speaking, the IVD antibody development services possess the capability to develop a wide scope of antibody species like monoclonal antibodies, polyclonal antibodies, antibody pair, recombinant antibodies against cancer, autoimmune diseases, infectious diseases, and cardiovascular diseases.

Features of Cancer IVD Development Services





Creative Biolabs specializes in custom antibody and assay development for the diagnosis of a variety of diseases and infections with experts who are able to develop high-affinity IVD antibodies against varies of markers. If more information about IVD antibodies discovery services is required, please feel free to visit

Like it? Share it!

Jerry Carter

About the Author

Jerry Carter
Joined: June 15th, 2019
Articles Posted: 52

More by this author